Related Experiment Video
Updated: May 29, 2026
07:20
Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
Published on: May 28, 2014
Novel rhein analogues as potential anticancer agents
Xiaochuan Yang1, Guojing Sun, Chunhao Yang
1Department of Chemistry and Center for Diagnostics and Therapeutics, Georgia State University, 100 Piedmont Ave., Atlanta, GA 30303-4098, USA.
Chemmedchem
|September 29, 2011
Summary
Researchers synthesized novel rhein analogues and tested their anticancer potential. One analogue demonstrated significant cytotoxicity against HeLa and MOLT4 cancer cell lines, indicating promising therapeutic properties.
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Cancer Biology
Background:
- Rhein, an anthraquinone, exhibits various biological activities.
- Modification of rhein's structure may lead to improved therapeutic agents.
- Targeting cancer cell proliferation is a key strategy in oncology.
Purpose of the Study:
- To synthesize novel rhein analogues with modifications at the 3-position.
- To evaluate the cytotoxic potential of these synthesized compounds against human cancer cell lines.
- To identify lead compounds with enhanced anticancer activity.
Main Methods:
- Chemical synthesis of two series of rhein analogues.
- Cytotoxicity assessment using the MTT assay.
- Determination of half-maximal inhibitory concentration (IC50) values.
Main Results:
- Several rhein analogues were successfully synthesized.
- One compound exhibited potent cytotoxicity against HeLa cells (IC50 = 2.7 μM).
- The same compound demonstrated superior potency against MOLT4 cells (IC50 = 0.6 μM).
Conclusions:
- Modification at the 3-position of rhein can yield compounds with significant cytotoxic activity.
- The identified lead compound shows promise for further development as an anticancer therapeutic.
- Further investigation into the mechanism of action is warranted.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...
01:46Electron Transport Chain: Complex I and II
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...